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Introduction: 
MondoA (MLX-interacting protein) is a bHLH transcription 
factor primarily located in skeletal muscle which drives 
glucose-dependent pathways such as glycolysis and the 
expression of TXNIP (thioredoxin-interacting protein). A 
Mondo-A/TXNIP feedback pathway has been defined 
previously which is believed to regulate the uptake of 
glucose by tumours in response to increased glycolysis and 
production of lactate1. The aim of this study was to profile 
MondoA protein expression in muscle-derived sarcomas and 
to determine how MondoA may interact with pathways 
associated with the Warburg Effect, lipid metabolism and 
pathways associated with sarcoma. 
Figure 1: Mondo A (Fast Red) 
immunohistochemistry showed 
underexpression of the protein in muscle-
derived sarcomas relative to normal  
tissue. (A) normal smooth muscle; (B) high 
grade malignant leiomyosarcoma;(C) 
normal skeletal muscle;  (D) pleiomorphic 
rhabdomyosarcoma. 
Methods: 
Immunohostochemical detection and semi-quantitative 
scoring of Mondo A protein expression was carried out in  
a commercially available tissue microarray composed of 
samples of sarcoma of a range of pathologies representing 
malignant progression versus normal smooth and striated 
muscle controls (Biomax #S02081). To explore the 
mechanistic basis of these observations, a statistical 
analysis of MondoA mRNA expression was carried out 
using data from a study involving human samples of 
sarcoma (data mined from Oncomine, Compendia 
Biosciences)2. From this data, the top 200 correlates with 
MondoA were calculated and Ingenuity Pathway Analysis® 
used to compile a network for comparison with key 
pathways involved in sarcoma and muscle development. 
  
 Results: 
IHC revealed a significant trend for 
decreased expression of Mondo A in 
sarcoma relative to normal tissue 
(One way ANOVA, P =<0.001) (figures 
1 and 2A). 
 
Figure 2: Relationshop between MondoA and malignant 
progression is shown in (A) and with cancer type in (B). 
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Figure 3: Network analysis (Ingenuity Knowledge Base) showing relationships 
of MondoA with up- and downstream mediators associated with sarcoma.  
Meanwhile, distribution of Mondo A mRNA (figure 
2B) also showed a trend for under expression with 
malignancy, although levels were highest in GIST 
tumours. MondoA correlates were represented in 
key pathways associated with sarcoma (P = 8.00E-
4) and skeletal and muscle disorders (P = 5.1E-05) 
and reflective of the function of MondoA as a 
glucose-responsive transcription factor, with 
significant representation of gene correlates in 
pathways involved with energy production (P 
=3.37E-21 - 1.09E-02), lipid (P = 3.37E-21 - 1.47E-02) 
and carbohydrate metabolism (P = 4.81E-11 - 
1.47E-02). Further network analysis via the 
Ingenuity Knowledge Base indicates that MondoA 
interacts with pathways mediated by PPARalpha 
and gamma, Mlx and TXNIP (figure 3).  
Conclusion: 
MondoA may behave as a tumour suppressor in sarcoma, by interfering 
with the increased demands for glycolysis and fatty acid production in 
malignancy.  This effect may be partially mediated via the MondoA target 
gene TXNIP. 
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